Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03299556 · ClinicalTrials.gov registry record
Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System
A clinical trial, sponsored by Purdue Pharma.
- Completed
- Registry status
- 420
- Enrollment target
NCT03299556: Completed study, sponsored by Purdue Pharma.
NCT03299556 is a clinical trial that has completed, run by Purdue Pharma. The registered enrollment target is 420 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03299556 has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- 420 participants
- Enrollment target
Study Summary
This is a proof of concept study to measure the effect of Wearable Health Technology (WHT), including the Apple Watch, iPhone, Pain App and Provider Dashboards on important clinical outcomes in patients treated for chronic pain. WHT will be tested in a group of chronic pain patients treated at a specialty pain clinic, the Geisinger Multidisciplinary Pain Program (MPP). Primary and secondary outcomes include pain, physical function, depression, pain medicine use, amount of sleep, activity levels, healthcare resource utilization and cost. The WHT will collect self-reported data on pain, pain management therapies, and medication utilization, and passively collected data on subject activity levels and sleep. Additional data will be collected on device utilization by patients and health care professionals.
Primary Outcome
self reported 11-point pain scale. The numeric pain score (NPS) is self-reported by the patient on a scale of 0 to 10, with the following scale labels: no pain (0), mild pain (2), moderate pain (4), severe pain (6), very severe pain (8), and worst pain possible (10).
Interventions
- OTHER WHT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2019-11-30 |
What the finished NCT03299556 record still lists
NCT03299556 is an observational study that tracks outcomes without assigning an intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which WHT is the first listed.
NCT03299556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03299556 about?
NCT03299556 is a clinical study titled "Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System". This is a proof of concept study to measure the effect of Wearable Health Technology (WHT), including the Apple Watch, iPhone, Pain App and Provider Dashboards on important clinical outcomes in patients treated for chronic pain. WHT will be tested in a group of chronic pain patients treated at a spe...
What is the current status of trial NCT03299556?
This trial is currently completed. The enrollment target is 420 participants. The study started on 2017-10-05. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT03299556?
The interventions under investigation include: WHT (OTHER).
Who is sponsoring clinical trial NCT03299556?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI